Business Context and Reporting Period
This Form 8-K Current Report is filed by Tharimmune, Inc. (not Canton Strategic Holdings, Inc.) on December 10, 2025. The filing discloses the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- New CFO Base Salary: $300,000 annually.
- Target Performance Bonus: $100,000 annually (cash-based, discretionary).
- Equity Awards: Eligible for time-based and/or performance-based grants (amount and form determined by the Board).
- Severance (Termination without Cause/Good Reason): 12 months of base salary plus accrued benefits.
Material Changes
Executive Leadership Change:
- Appointment: Jacob Asbury (age 52) was appointed Chief Financial Officer, effective December 10, 2025.
- Departure: Sireesh Appajosyula stepped down as Interim Chief Financial Officer. He will continue to serve as Chief Executive Officer of Gravitas Life Sciences, Inc., a subsidiary of Tharimmune, Inc., with no changes to his employment terms other than the role change.
Outlook, Risks, and Unusual Items
Management Commentary and Risks:
- The filing includes a press release (Exhibit 99.1) containing forward-looking statements regarding the new CFO's appointment.
- Standard risk disclosures note that forward-looking statements involve uncertainties and actual results may differ materially.
- The employment agreement is "at-will" and includes customary non-compete, non-solicitation, and confidentiality provisions.
Investor Verification Checklist
- Verify the full text of the CFO Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Review the Press Release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Confirm the current status of Gravitas Life Sciences, Inc. as a subsidiary and Mr. Appajosyula's ongoing role there.
- Note that the filing explicitly states it does not provide financial metrics; refer to the most recent 10-K or 10-Q for financial health data.